Prostate Region-Wise Imaging Biomarker Profiles for Risk Stratification and Biochemical Recurrence Prediction
In prostate cancer (PCa), precise risk stratification and awareness of potential biochemical recurrence (BCR) are essential for personalized treatment decisions. Magnetic resonance imaging (MRI) and radiomics extract quantitative parameters from images and are pivotal in PCa management. Combining both can predict critical clinical outcomes.
This study aims to identify MRI-extracted imaging biomarker profiles (including radiomic, perfusion, and diffusion features) to categorize PCa patients by risk and 10-year post-diagnosis BCR occurrence and assess their predictive value alongside clinical data.
Radiomic heterogeneity-related features were elevated in patients with poorer prognoses and BCR. Imaging biomarkers demonstrated substantial predictive ability (AUC > 0.725), improving with clinical data inclusion (AUC 0.841-0.877, sensitivity > 0.960 for combined models predicting BCR).
Prostate region-specific imaging profiles facilitate the identification of patients at higher risk of poor prognosis and BCR, offering enhanced predictive accuracy when paired with clinical variables.
Sánchez Iglesias Á, Morillo Macías V, Picó Peris A, Fuster-Matanzo A, Nogué Infante A, Muelas Soria R, Bellvís Bataller F, Domingo Pomar M, Casillas Meléndez C, Yébana Huertas R, et al. Prostate Region-Wise Imaging Biomarker Profiles for Risk Stratification and Biochemical Recurrence Prediction. Cancers. 2023; 15(16):4163